Bosh sahifaMOLN • NASDAQ
add
Molecular Partners AG
Yopilish kursi
4,71 $
Kunlik diapazon
4,10 $ - 4,63 $
Yillik diapazon
3,36 $ - 5,36 $
Bozor kapitalizatsiyasi
173,55 mln USD
Oʻrtacha hajm
2,87 ming
Narx/foyda
-
Dividend daromadliligi
-
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (CHF) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 43,62 mln | 716,09% |
Sof foyda | -12,65 mln | -12,62% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -0,36 | -20,00% |
EBITDA | -12,15 mln | 16,45% |
Amaldagi soliq stavkasi | -0,03% | — |
Balans
Jami aktivlari
Jami passivlari
| (CHF) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 93,06 mln | -37,73% |
Jami aktivlari | 102,11 mln | -35,59% |
Jami passivlari | 21,77 mln | 28,90% |
Umumiy kapital | 80,33 mln | — |
Tarqatilgan aksiyalar | 37,79 mln | — |
Narxi/balansdagi bahosi | 2,21 | — |
Aktivlardan daromad | -29,56% | — |
Kapitaldan daromad | -34,98% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (CHF) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -12,65 mln | -12,62% |
Operatsiyalardan naqd pul | -11,15 mln | 15,49% |
Sarmoyadan naqd pul | 11,95 mln | 365,95% |
Moliyadan naqd pul | -300,00 ming | -101,96% |
Naqd pulning sof oʻzgarishi | 294,00 ming | 115,65% |
Boʻsh pul | -15,02 mln | -136,94% |
Haqida
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Tashkil etilgan
2004
Xodimlar soni
153
